Chronic Knee Effusions in Patients With Advanced Osteoarthritis

Implications for Functional Outcome of Viscosupplementation

David D. Waddell, MD
Andrew A. Marino, PhD

ABSTRACT: Intra-articular injection of exogenous hyaluronan (viscosupplementation) is an effective treatment for knee pain due to osteoarthritis, but the amount of dilution of the viscosuplement by the synovial fluid, which could affect efficacy, has not been previously considered. In this study, the synovial fluid volume was measured in patients with advanced osteoarthritis and the variation in viscosuplement concentration that would have occurred had the patients received that treatment was calculated. A closed aspiration was performed under anesthesia in this consecutive, prospective series of patients undergoing total joint arthroplasty for advanced osteoarthritis. Any remaining synovial fluid was collected by means of open aspiration following an arthrotomy. Overall, 27.0±15.5 mL (range: 10-70 mL) of synovial fluid was present in the joints. Irrespective of the particular proprietary hyaluronan product, the viscosuplement concentration would have varied by an approximate factor of 6. Intertreatment variation in volume of synovial fluid may explain some of the observed variations in efficacy in patients treated with viscosupplementation. Stricter attention to the possibility of a joint effusion and aspiration of the joint where indicated might lead to improved results.


INTRODUCTION

The prevalence of osteoarthritis increases with age throughout the knee pain, weight reduction, topicals, and exercise. Nonsteroidal anti-inflammatory agents frequently are used to relieve pain, but they have drawbacks, particularly gastrointestinal irritation. Cyclooxygenase-2 inhibitors are alternatives, but they also are associated with side effects. Corticosteroid therapy and total knee replacement usually are reserved for patients with severe disease when other therapies have failed. Injection of the knee with hyaluronan (viscosupplementation) is an alternative for patients who have not had success with basic analgesics, are not surgical candidates, or want to delay surgery.

Although viscosupplementation can provide relief of knee pain due to osteoarthritis, wide inter- and intratreatment variations in therapeutic efficacy have been reported. The variability in outcome success may have been due to the extent of the disease, the viscosity or elasticity of the hyaluronan products, injection technique, or any combination of these or other factors. Another possible and previously unconsidered explanation is dilution of the viscosuplement by the synovial fluid.

Prior to addressing this question directly in a clinical study, we thought it worthwhile to first assess whether any evidence to support the hypothesis exists. The objective of this study was to measure the volume of synovial fluid in pa-
Patients with advanced osteoarthritis and to calculate the corresponding variability in viscosupplement concentration under the assumption the patients had received that treatment.

PATIENTS AND METHODS

Patients in this study were recruited from one author’s practice (D.D.W.), which specializes in treating problems involving the knee. The volume of synovial fluid in the knee was measured in a prospective series of 19 patients with advanced osteoarthritis (grade IV, Kellgren–Lawrence scale); only patients who were candidates for total joint arthroplasty were studied. Average patient age was 69.6±8.3 years (range: 54–80 years). Knee effusion was subjectively graded; no effusion was noted clinically in 14 cases and 5 cases had mild effusion.

After induction of anesthesia, a closed aspiration was performed at the standard superolateral arthroscopy portal using a 21-gauge, 3-inch spinal needle with the knee in extension and the patient supine. An additional aspiration attempt was made with the knee flexed and the needle inserted in the anterolateral compartment from an anterior approach; any additional fluid obtained was pooled with that aspirated initially. To ensure that all synovial fluid in the joint was recovered, a standard arthroscopy was performed and any fluid in the suprapatellar pouch, medial compartment, lateral compartment, or intercondylar notch was collected by means of open aspiration and added to that previously obtained. The measured fluid volumes were uncorrelated with age, weight, gender, pain, or the clinical judgment regarding the presence of an effusion, and therefore the data were grouped without regard to these variables.

All experimental procedures were approved by the Institutional Review Board for Human Research at our institution.

RESULTS

The average volume of synovial fluid obtained by closed aspiration in 19 patients was 19.4±14.4 mL (range: 3–62 mL). Following an arthroscopy, an additional 7.1±2.9 mL of synovial fluid was obtained (range: 3–13 mL). Overall, 27.5±15.5 mL (range: 10–70 mL) of synovial fluid was present in the joints. The volumes of synovial fluid obtained during closed and open aspirations did not correlate (Figure).

DISCUSSION

The normal knee contains 1–4 mL of synovial fluid.8,9 The fluid volume in patients with osteoarthritis generally is known to be greater, but it had not previously been documented among patients with grade IV disease. The fluid volume was measured to assess the hypothesis of variable interpatient viscosupplement dilution.

The interpatient range of fluid volumes in a prospective series of 19 cases was 10–70 mL. Suppose that these joints had been injected with a mg of proprietary hyaluronan product dissolved in a volume v. Assuming complete mixing of the synovial fluid and the viscosupplement, regardless of the actual value of \( v \) (Table), the variability within the cases (ratio of the maximum to minimum concentration) would be \((70+v)/(10+v)\), which equals 6.0 for \( v=2 \) mL (Figure). In other words, the concentration of the viscosupplement would have varied among the cases by a factor of 6.0. In practice, it is unlikely that complete mixing occurs prior to the onset of metabolic action of the viscosupplement, thus adding to the interpatient variability in viscosupplement concentration.

Compared with the interpatient variation in dilution resulting from differences in synovial fluid volume, the variations in endogenous hyaluronan concentration in the synovial fluid among patients with osteoarthritis is negligible.7,10 Consequently, interpatient differences in endogenous hyaluronan probably have no bearing on the differences in efficacy of viscosupplementation.

The severity of the osteoarthritis in patients who receive viscosupplementation varies widely among practitioners.17 In one author’s practice (D.D.W.), 71% of 1047 patients had grade IV radiographic disease.16 Thus, the group of patients studied herein was representative of the typical patient seen in this practice.

The original rationale for viscosupplementation was
TABLE
PERTINENT LABEL DATA OF FOUR VISCOSUSPLEMENTS* APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF KNEE PAIN DUE TO OSTEOARTHRITIS

<table>
<thead>
<tr>
<th>Viscosupplement</th>
<th>Concentration (mg/mL)</th>
<th>Injection Volume (mL)</th>
<th>Dose (mg)</th>
<th>Molecular Weight (MDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthovisc</td>
<td>15</td>
<td>2.0</td>
<td>30</td>
<td>1.0-2.9</td>
</tr>
<tr>
<td>Supartz</td>
<td>10</td>
<td>2.5</td>
<td>25</td>
<td>0.6-1.2</td>
</tr>
<tr>
<td>Hyalgan</td>
<td>10</td>
<td>2.0</td>
<td>20</td>
<td>0.5-0.7</td>
</tr>
<tr>
<td>Synvisc</td>
<td>8</td>
<td>2.0</td>
<td>16</td>
<td>6.0</td>
</tr>
</tbody>
</table>

*Orthovisc, Ortho Biotech Products, Bridgewater, NJ; Supartz (Artz), Smith & Nephew, Memphis, Tenn; Hyalgan, Fidia, Turin, Italy; and Synvisc, Genzyme Biosurgery, Ridgefield, N.J.

that it partially restored the viscoelasticity of synovial fluid that had decreased due to disease-related changes in the endogenous hyaluronan in the synovial fluid.\(^7\) The viscosity of synovial fluid is a complex function of the hyaluronan molecular weight and concentration\(^1,2\) but, in general, changes of 0.5-1.0 mg/mL can affect viscoelasticity. Subsequent work suggested that the therapeutic efficacy of viscosupplementation was partly related to signaling of hyaluronan through receptors on synovial cells such as CD44.\(^11\) Signaling by an agent is directly dependent on its concentration. Consequently, irrespective of whether the clinical effects of exogenous hyaluronan have a physiochemical or physiological basis, the variation in efficacy following intra-articular injection of hyaluronan might be at least partially explained by the dilution hypothesis because both modes of action are concentration-dependent.

Intra-articular injection of steroids produced a rapid improvement in symptoms (1-2 weeks), but efficacy decreased with time; viscosupplementation, in contrast, had a slower onset of efficacy but a greater improvement \((P<.05)\) at 12-26 weeks.\(^3\) However, the influence of effusion on efficacy (for both treatments) is not well understood. The product labels for viscosupplements recommend that any joint effusion be removed before injection of the product.\(^12,13\) Effusions are sometimes aspirated prior to viscosupplementation, but clinical practices regarding identification and aspiration of an effusion vary widely. For example, in 17 prospective controlled clinical studies,\(^17\) the authors of 5 studies did not comment on whether they had aspirated the joints. In the remaining 12 studies, all patients were aspirated in 3 studies and variable numbers of patients were aspirated in the remaining 9 studies. It appears that joint aspiration was a significant uncontrolled factor that could explain at least part of the observed variability in treatment efficacy.

The extent of the variation in the volume of synovial fluid in the knee of patients with grade IV osteoarthritis supported the hypothesis that variability in response to viscosupplementation results at least partially from its dilution by the synovial fluid in the joint thereby justifying a direct, prospective clinical study. In the meantime, stricter attention to the possibility of an effusion and aspiration of the joint where indicated might lead to improved results in joints injected with a viscosupplement.

REFERENCES